Sharon E. Plon, MD, PhD, FACMG
Department or Service
- Texas Medical Center
- Genetics and Genomics
Director, Baylor Cancer Genetics Clinics
Co-Director, Cancer Genetics and Genomics Program
Principal Investigator, Cancer Genetics and Genomics Research Laboratories
Professor, Department of Pediatrics, Section of Hematology-Oncology, Department of Molecular and Human Genetics and Human Genome Sequencing Center, Baylor College of Medicine
Faculty Member, Genetics and Genomics and the Cancer and Cell Biology graduate programs, The Graduate School of Biomedical Sciences, Baylor College of Medicine
Director, M.D./Ph.D. Medical Scientist Training Program, Baylor College of Medicine
|Harvard Medical School||medical school||Doctor of Medicine||1987|
|Harvard University||PhD||Doctor of Philosophy, Biophysics||1987|
|Massachusetts Institute of Technology||bachelors||Bachelor of Science, Chemistry||1979|
|Massachusetts Institute of Technology||bachelors||Bachelor of Science, Chemical Engineering||1980|
|University of Washington||fellowship||Clinical Genetics||1993|
|NIH/NIAID||fellowship||Postdoctoral Research Fellowship, Cancer Genetics||1990|
|University of Washington||internship||Internal Medicine||1988|
Dr. Sharon Plon is a board-certified medical geneticist having completed her genetics training at the University of Washington. Dr. Plon has been at Baylor College of Medicine for 25 years and founded and continues to direct the Cancer Genetics Clinic at Texas Children’s Hospital. Dr. Plon serves on the National Advisory Council for Human Genome Research of the National Institutes of Health (NIH) and serves on the Board of Directors of the American Society of Human Genetics. Dr. Plon has also worked with the American Association of Cancer Research to develop an online resource for physicians with up to date recommendations for cancer surveillance in those children at genetic risk of cancer.
|American Association Cancer Research (AACR)||Member|
|American College of Medical Genetics and Genomics (ACMG)||Founding Member|
|American Society Human Genetics (ASHG)||Board of Directors|
Dr. Plon’s translational research has focused on analysis of patients with inherited susceptibility to childhood cancer, for example Rothmund Thomson syndrome associated with mutations in the RECQL4 gene and predisposition to osteosarcoma. Over the last ten years her research group has also reported on novel mechanisms of AML predisposition (microdeletion of 21q22), a novel chromosome breakage syndrome (LICS) and enrolling and interrogating the constitutional genome in families with unusual patterns of childhood cancer and congenital anomalies through whole genome and exome sequencing.
Dr. Plon serves as co-PI with D. William Parsons and Amy McGuire of the recently renewed NHGRI/NCI sponsored clinical sequencing exploratory research (CSER) project at BCM on incorporating CLIA clinical genome-scale exome sequencing into the care of newly diagnosed childhood cancer patients (solid tumors and brain tumors) in the diverse patient populations across five sites in Texas. The initial CSER study (BASIC3) revealed that approximately 10% of unselected children with cancer have underlying cancer susceptibility mutations.
In 2013, Dr. Plon was name co-Principal investigator of the NHGRI U01 grant with Carlos Bustamante to support the development of a comprehensive Clinical Genomics (ClinGen).
Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, Kerstein RA, Gutierrez S, Petersen AK, Bavle A, Lin FY, Lopez-Terrada DH, Monzon FA, Hicks MJ, Eldin KW, Quintanilla NM, Adesina AM, Mohila CA, Whitehead W, Jea A, Vasudevan SA, Nuchtern JG, Ramamurthy U, McGuire AL, Hilsenbeck SG, Reid JG, Muzny DM, Wheeler DA, Berg SL, Chintagumpala MM, Eng CM, Gibbs RA, Plon SE (2016). Diagnostic Yield of Clinical Tumor and Germline Whole Exome Sequencing for Children with Solid Tumors. JAMA Oncology, JAMA Oncol. Epub January 28, 2016.
van der Crabben SN, Hennus MP, McGregor G, Ritter DI, Nagamani SC, Wells OS, Harakalova M, Chinn IK, Alt A, Vondrova L, Hochstenbach R, van Montfrans JM, Terheggen-Lagro SW, van Lieshout S, van Roosmalen MJ, Renkens I, Duran K, Nijman IJ, Kloosterman WP, Hennekam E, Orange JS, van Hasselt PM, Wheeler DA, Palecek JJ, Lehmann AR, Oliver AW, Pearl LH, +Plon SE, +Murray JM, +van Haaften G (2016). Chromosome breakage syndrome with severe lung disease through destabilized SMC5/6 complex. JCI, 126(8):2881-92. +co-senior authors.
Rehm HL, Berg JS, Brooks LD, Bustamante CD, Evans JP, Landrum MJ, Ledbetter DH, Maglott DR, Martin CL, Nussbaum RL, Plon SE, Ramos EM, Sherry ST, Watson MS (2015). ClinGen: The Clinical Genome Resource, New England J Medicine, Jun 4;372(23):2235-42.